Ustekinumab is a new drug to treat psoriasis and psoriatic arthritis

Корсакова, Ю. Л.; Stanislav, Marina; Denisov, L N; Насонов, Евгений Львович

doi:10.14412/1995-4484-2013-646

Cited by 4 publications

(5 citation statements)

References 50 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Увеличение концентрации ИЛ22 в сыворотках больных СШ коррелирует с выраженностью ксеросто-мии, увеличением концентрации ревматоидного фактора (РФ), анти-SSB-антител и гипергаммаглобулинемией [126]. В периферической крови пациентов с СШ отмеча-ется увеличение субпопуляции Th17-клеток (CD4+CD161+), ассоциирующееся с активностью (ин-декс ESSDAI ≥4), лабораторными параметрами (СОЭ, гипергаммаглобулинемия, тромбоцитопения, анти-SSB) и тяжестью заболевания [127] Фармакотерапия ИЛ17-ассоциированных иммуновоспалительных заболеваний: фокус на секукинумаб Впервые терапевтическая эффективность ингибиции Th17-клеток и синтеза ИЛ17 при ИВЗ человека была про-демонстрирована у пациентов с псориазом, получавших лечение препаратом устекинумаб, который представляет собой мАТ к ИЛ12/ИЛ23 [128]. Однако, поскольку эти ан-титела ингибируют не только Th17-, но и Th1-тип иммун-ного ответа, клиническое значение подавления активации именно Th17 оставалось не доказанным.…”

Section: синдром шегренаunclassified

New Possibilities of Pharmacotherapy for Immunoinflammatory Rheumatic Diseases: A Focus on Inhibitors of Interleukin-17

Насонов¹

2017

rsp

View full text Add to dashboard Cite

Section: синдром шегренаunclassified

New Possibilities of Pharmacotherapy for Immunoinflammatory Rheumatic Diseases: A Focus on Inhibitors of Interleukin-17

Насонов¹

2017

rsp

View full text Add to dashboard Cite

“…They produce their biological action by fixing on double-stranded heterodimeric receptor complexes located on the surface of CD4 + T lymphocytes and natural killer cells (NK cells). IL-23 stimulates Th17-lymphocytes that begin to produce proinflammatory factors, including IL-17, and these induce synthesis of other proinflammatory agents, according to the feedback principle [ 4 – 7 ].…”

Section: Introductionmentioning

confidence: 99%

Sorption of Interleukins 12 and 23 Using the Developed Magnetocontrollable Ustekinumab-Based Sorbent

Gontar¹,

Emelyanova²,

Русанова³

et al. 2020

Sovrem Tehnol Med

View full text Add to dashboard Cite

The aim of the study was to assess the sorption capacity of Ustekinumab, a drug based on interleukins 12 (IL-12) and 23 (IL-23), when using it with a magnetocontrollable sorbent. Materials and Methods. To reduce the concentration of proinflammatory cytokines (IL-12, IL-23), the blood of patients with psoriatic arthritis was passed through magnetocontrollable polyacrylamide granules (MPG) of spherical shape with the particle size of 10-100 µm, obtained by emulsion polymerization. Perfusion was performed through a 10 ml column equipped with an electromagnet, into which MPG with immobilized antibodies to IL-12 and IL-23 was added. Ustekinumab, a commercial drug with concentration of monoclonal antibodies equaling 0.2 mg per 1 ml of saline was used as the source of antibodies to these interleukins. The specific sorption capacity of MPG was determined using a column filled with the granules in a volume of 0.2 ml and inducing their subsequent interaction with 1 ml of IL-12 and IL-23 solutions with increasing concentrations. The heparinized blood of 10 patients with psoriatic arthritis of various degrees of activity, who had no parenteral administration of IL-12/IL-23 inhibitors (Ustekinumab) for 12 months, was subjected to in vitro treatment. The blood of 10 healthy donors was used as the control; the perfusion procedure was similar. Results. Digital parameters were measured for each sample before and after the interaction between the sorbent and blood plasma. There was a significant decrease in cytokines from the baseline-by 99.8% (in donors) and by 99.9% (in patients). When using a carbon sorbent, their concentration decreases by 92.6% from the baseline. As a result of sorption, blood cell counts did not change reliably, which is an additional positive aspect of this procedure. Conclusion. The maximum possible decrease in the level of cytokines has great practical importance, since they play a leading role in the pathogenesis of psoriatic arthritis. The use of a synthesized Ustekinumab-based sorbent is a highly effective way of removing them simultaneously from blood plasma.

show abstract

“…УСТ представляет собой моноклональное антитело к субъединице р40 ИЛ12/23. Блокада ИЛ12/23 высокоэффективна при псориазе, что подтверждено в различных РКИ [4,7,24,28]. Так, в исследованиях PHOENIX 1 и PHOENIX 2 продемонстрирована высокая эффективность УСТ в сравнении с плацебо у пациентов со среднетяжелым и тяжелым псориазом: к 12-й неделе лечения 75% улучшение по индексу PASI достигнуто у 67,1% больных, получавших УСТ по 45 мг, и у 66,4% -при дозе 90 мг [29,30].…”

unclassified

Difficulties in choosing a biologic disease-modifying anti-rheumatic drug for the treatment of psoriasis and psoriatic arthritis

Марусенко

Везикова

Кондричина

et al. 2019

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

The article presents a clinical observation of a patient with severe psoriasis and psoriatic arthritis. Due to insufficient efficacy of systemic therapy of psoriasis biologic disease-modifying therapy was started, but it was associated with difficulties. Development of erythrodermic form of psoriasis was observed during treatment with infliximab and abatacept was successfully used though it is not registered inRussiafor the treatment of psoriasis.

show abstract

Ustekinumab is a new drug to treat psoriasis and psoriatic arthritis

Cited by 4 publications

References 50 publications

New Possibilities of Pharmacotherapy for Immunoinflammatory Rheumatic Diseases: A Focus on Inhibitors of Interleukin-17

New Possibilities of Pharmacotherapy for Immunoinflammatory Rheumatic Diseases: A Focus on Inhibitors of Interleukin-17

Sorption of Interleukins 12 and 23 Using the Developed Magnetocontrollable Ustekinumab-Based Sorbent

Difficulties in choosing a biologic disease-modifying anti-rheumatic drug for the treatment of psoriasis and psoriatic arthritis

Contact Info

Product

Resources

About